{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:17:32Z","timestamp":1793927852345,"version":"4.8.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001934","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jaad.2023.08.102","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:01:42Z","timestamp":1699344102000},"page":"e43-e56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":280,"title":["Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies"],"prefix":"10.1016","volume":"90","author":[{"given":"Dawn M.R.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Bercovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsy","family":"Frazer-Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Schwarzenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sidbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.08.102_bib1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/DER.0000000000000208","article-title":"A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion","volume":"27","author":"Chen","year":"2016","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2023.08.102_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2023.08.102_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2023.08.102_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2023.08.102_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib10","article-title":"Leukotriene receptor antagonists for eczema","volume":"10","author":"Ferguson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2023.08.102_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2023.08.102_bib12","first-page":"CD013870","article-title":"Phototherapy for atopic eczema","volume":"10","author":"Musters","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2023.08.102_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2340\/00015555-3089","article-title":"Changes in lesional and non-lesional skin microbiome during treatment of atopic dermatitis","volume":"99","author":"Kwon","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.08.102_bib14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(00)05114-X","article-title":"Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial","volume":"357","author":"Reynolds","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib15","first-page":"34","article-title":"Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis","volume":"86","author":"Tzung","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.08.102_bib16","first-page":"1","article-title":"Glycerol 85% efficacy on atopic skin and its microbiome: a randomized controlled trial with clinical and bacteriological evaluation","volume":"332","author":"Youssef","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.08.102_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.08.102_bib18","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.08.102_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","article-title":"Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"85","author":"Merola","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib26","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.08.102_bib28","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.21630","volume":"187","author":"Bieber","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.jaad.2023.08.102_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2017.07.007","article-title":"Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial","volume":"6","author":"Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.08.102_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.08.102_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","article-title":"Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial","volume":"162","author":"Schmitt","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/09546634.2019.1642996","article-title":"Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis","volume":"31","author":"Phan","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.08.102_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib44","first-page":"653","article-title":"A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life","volume":"42","author":"Czech","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/000155501750208137","article-title":"Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis","volume":"81","author":"Granlund","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.08.102_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fmed.2014.00033","article-title":"Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities","volume":"1","author":"Koppelhus","year":"2014","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2023.08.102_bib47","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2222.2004.1907.x","article-title":"Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study","volume":"34","author":"Pacor","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaad.2023.08.102_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.1993.tb03170.x","article-title":"Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial","volume":"129","author":"Salek","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with\u00a0severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib51","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"van Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.08.102_bib53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clindermatol.2016.05.011","article-title":"Phototherapy for atopic dermatitis","volume":"34","author":"Rodenbeck","year":"2016","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib54","first-page":"555","article-title":"Skin cancer\u00a0after PUVA treatment for psoriasis","volume":"301","author":"Stern","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.08.102_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2021.11.048","article-title":"Incidence of skin cancers in patients with eczema treated with ultraviolet phototherapy","volume":"87","author":"Ahad","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.08.102_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/DER.0000000000000845","article-title":"Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and International Eczema Council Survey","volume":"33","author":"Drucker","year":"2022","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2023.08.102_bib59","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.jaad.2023.08.102_bib60","series-title":"FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death For Jak Inhibitors That Treat Certain Chronic Inflammatory Conditions","year":"2021"},{"key":"10.1016\/j.jaad.2023.08.102_bib61","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.08.102_bib63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib64","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral\u00a0corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2023.08.102_bib65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib66","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","article-title":"Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review","volume":"156","author":"Lam","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.08.102_bib67","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.08.102_bib68","first-page":"540","article-title":"Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) initiative","volume":"179","author":"Grinich","year":"2018","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223028785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223028785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T09:10:46Z","timestamp":1723281046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223028785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0190962223028785"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}